Business Wire

TEJ-KOHLI-FOUNDATION

19.12.2019 14:11:12 CET | Business Wire | Press release

Share
5,736 of the World’s Poorest People Received the Gift of Sight in 2019 at the Tej Kohli Cornea Institute

On the fourth anniversary of the Tej Kohli Cornea Institute in Hyderabad, the Tej Kohli Foundation has renewed its commitment of $14m of funding from 2020. During 2019 5,736 individuals were cured of blindness or severe visual impairment at The Tej Kohli Cornea Institute, which is a collaboration between the Tej Kohli Foundation in London, and the LV Prasad Eye Institute in Hyderabad, a World Health Organization Collaborating Centre.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191219005417/en/

The Tej Kohli Cornea Institute was inaugurated in December 2015 to tackle the problem of poverty blindness by providing free treatment to anyone who needs it. Since its inauguration the Cornea Institute has taken care of 223,404 outpatients, completed 43,255 surgical procedures, collected 38,225 donor corneas into its eye bank, utilized 22,176 donor corneas, trained 152 clinicians, published 202 papers and given 892 educational presentations.

Reaching people living with blindness and severe visual impairment in the hard-to-reach rural areas where 66% of Indians live is a particular challenge that the Tej Kohli Cornea Institute is uniquely solving. A unique presence of eye care centres in villages supplemented with a fully equipped mobile diagnostics van take eye care directly to hard-to-reach patients, with more than 100 corneal transplants completed so far in these rural areas.

Other 2019 operational highlights at the Tej Kohli Cornea Institute included:

  • 280,000 individuals called the ‘Call Netra’ toll free eye care helpline.
  • A special privilege ‘Keratoplasty card’ was issued to corneal transplant patients to ensure priority check-ups and access to care anytime and anywhere.
  • An education app was launched to continually assess cornea doctors in their evaluations.
  • The ECHO project linked expert specialist teams with clinicians in remote local communities.

According to the World Health Organisation, 90% of those affected by blindness and severe visual impairment live in the poorest countries in the world. 14m live in India, where between 6m and 7m people are currently waiting for a corneal transplant. At least 300,000 children in India have some form of severe visual impairment or blindness.

Whilst approximately 75% of corneal disease is curable, the costs of corneal transplantation surgery using donor cornea, and the many years of medicine needed to prevent rejection, makes treatment inaccessible to many. Born out of a partnership with the LV Prasad Eye Institute and the Tej Kohli Foundation, the Tej Kohli Cornea Institute is focussed on prevention, treatment and cure at no cost directly into these high-impact populations that are living needlessly with corneal blindness.

Dr Pravin K Vaddavalli, MD, Director of Tej Kohli Cornea Institute said:

“The last four years have been an opportunity to assess the magnitude of the problem of corneal blindness, create strategic partnerships to expand our reach and start to evolve ways and means to allow these patients to live longer, more productively and with dignity.”

Wendy Kohli, co-Founder of the Tej Kohli Foundation said:

“It’s an uncomfortable reality that millions of people worldwide are living with curable blindness that persists entirely because they cannot afford to access treatment. The impact of restoring a person’s vision on that person’s confidence, wellbeing and economic prospects is substantial. Through the Tej Kohli Cornea Institute we are able to make direct interventions into individual lives that help and transform entire families every single day.”

---

About The Tej Kohli Cornea Institute

The mission of the Tej Kohli Cornea Institute is to prevent, control and eliminate corneal blindness worldwide. The Institute is a global leader in research and development, preventative medicine, education and cornea transplants. The Institute enables access to affordable treatment through systemic long-term efforts to create widespread access to high-quality eye care facilities that are delivered by people with the resources, technical skills and compassion to handle diverse population segments.

http://www.tejkohlicorneainstitute.com

About LV Prasad Eye Institute

Established in 1987, the LV Prasad Eye Institute (LVPEI), a World Health Organization Collaborating Centre for Prevention of Blindness, is a comprehensive eye health facility. The Institute has ten active arms to its areas of operations: Clinical Services, Education, Research, Vision Rehabilitation, Rural and Community Eye Health, Eye Banking, Advocacy and Policy Planning, Capacity Building, Innovation and Product Development. LVPEI's mission is to provide equitable and quality eye care to all sections of society.

http://www.lvpei.org

About the Tej Kohli Foundation

Founded in 2005, the Tej Kohli Foundation seeks to make interventions that transform individual lives. It is best known for its global mission to end corneal blindness worldwide. Since 2015 the Foundation has funded the provision of corneal transplants in underserved communities in India through the Tej Kohli Cornea Institute; and in 2019 the Foundation gifted $2m to Mass Eye and Ear in Boston, a teaching hospital of Harvard Medical School, to support the development of new technologies to cure blindness. In December 2019 the Foundation launched the ‘Future Bionics’ program to gift 3D printed bionic arms to children and young people who are living with limb difference in the United Kingdom.

http://www.tejkohlifoundation.com

END

Social Media:

https://www.facebook.com/TejKohliFoundation/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye